Abstract
Sickle cell disease (SCD) is an inheritable genetic disorder hallmarked by a single point mutation in the β-globin chain resulting in abnormal polymerization of deoxygenated hemoglobin and subsequent sickling of the erythrocyte. Longevity in SCD patients has greatly increased, shifting the paradigm for cause of death from acute to chronic conditions. Endothelial dysfunction attributed to SCD triggers a cascade of inflammatory biomarkers known to mediate several cardiovascular complications, however, the etiology of heart disease in SCD remains unclear. Cardiovascular manifestations resulting in premature mortality include elevated cardiac output, systolic and diastolic dysfunction, pulmonary hypertension, and sudden cardiac death. This review explores relevant biomarkers of inflammation typically observed as mediators or indicators of cardiovascular disease (CVD) as well as current literature on cardiovascular complications found in those with SCD. Additionally, the potential role of CVD treatments to manage the severity of SCD will be explored.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
National Heart, Lung, and Blood Institute. Disease and conditions index. Sickle cell anemia: who is at risk? Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhoIsAtRisk.html. Accessed March 2013.
• Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol. 2012;59:1123–33. Offers insight in review of cardiovascular conditions in SCD.
Epstein HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–9.
Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica. 2006;91(1):7–10.
Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983–2002. J Pediatr. 2009;154(4):541–5.
Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.
•• Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010;85(1):36–40. Comprehensive view of mortality in SCD patients.
Manci EA, Culberson DE, Yang Y, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123(2):359–65.
Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4- decade observational study of 1056 patients. Medicine (Baltimore). 2005;84(6):363–76.
Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858–63.
Kato GJ, McGowan VR, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood. 2006;107:2279–85.
Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
Al-Habboubi HH, Mahdi N, Abu-Hijleh TM, et al. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasooclusive crisis in sickle cell disease. Haematology. 2012;89:403–9.
Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine and new research directions. J Haematol. 2009;84(9):618–25.
Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematol Am Soc Hematol Educ Program. 2007; 84–90.
Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood. 2012;102(7):2678–83.
• Adam SS, Hoppe C. Potential role for statins in sickle cell disease. Pediatr Blood Cancer. 2013;60(4):550–7. One of few papers that reviews statins in SCD.
Voskaridou E, Christoulas D, Terpos E. Sickle cell disease and the heart: review of the current literature. Br J Haematol. 2012;157(6):664–73.
Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001;97(7):1937–41.
Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96(7):2451–9.
Hibbert JM, Hsu LL, Bhathena SJ, et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp Biol Med (Maywood). 2005;230(1):68–74.
Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed). 2009;1:391–405.
Inoshima I, Kuwano K, Hamada N, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286(5):L1038–44.
Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000;95(10):3032–43.
Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012;18(2):195–200.
Selvaraj SK, Giri RK, Perelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102(4):1515–24. Epub 2003 Apr 10.
Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1α. Blood. 2008;112(3):856–65.
Heresi GA, Dweik RA. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32(2):503–12.
• Sundaram N, Tailor A, Mendelsohn L, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109–12. Offers novel mechanism for PHTN via hemolysis.
Ikeda Y, Yonemitsu Y, Kataoka C, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2002;283(5):H2021–8.
Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology. 2003;8(5):329–37.
Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203–17.
Francis RB, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992;84(7):611–5.
Asare K, Gee BE, Stiles JK, et al. Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease. Cytokine. 2010;49(1):39–44.
Keikhaei B, Mohseni AR, Norouzirad R, et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013;24(1):45–52.
Musa BOP, Onyemelukwe GC, Hambolu JO, et al. Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol. 2010;17(4):602–8.
Brière F, Bridon JM, Chevet D, et al. Interleukin 10 induces B lymphocytes from IgA-deficient patientsto secrete IgA. J Clin Invest. 1994;94(1):97–104.
Barbosa MC, Jesus dos Santos TE, Félix de Souza G, et al. Impact of iron overload on interleukin-10 levels, biochemical parameters and oxidative stress in patients with sickle cell anemia. Rev Bras Hematol Hemoter. 2013;35(1):29–34.
Taylor SC, Shacks SJ, Qu Z, Wiley P. Type 2 cytokine serum levels in healthy sickle cell disease patients. J Natl Med Assoc. 1997;89:753–7.
Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Hematol J. 2008;93(1):20–6.
Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310–8.
Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98:525–9.
Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32(2):503–12.
Albert MA, Ridker PM. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference. Circulation. 2006;114:e67–74.
Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004;148(1):19–26.
Krishnan S, Setty Y, Betal SG, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol. 2010;148(5):797–804.
Datta S, Iqbal Z, Prasad KR. Comparison between serum hsCRP and LDL cholesterol for search of a better predictor for ischemic heart disease. Indian J Clin Biochem. 2011;26(2):210–3.
The Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.
Kanavaki I, Makrythanasis P, Lazaropoulou C, et al. Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta-thalassaemia. Eur J Clin Invest. 2012;42(1):27–33.
Akohoue SA, Shankar S, Milne GL, et al. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr Res. 2007;61:233–8.
Mohammed FA, Mahdi N, Sater MA, et al. The relation of C-reactive protein to vasoocclusive crisis in children with sickle cell disease. Blood Cells Mol Dis. 2010;45(4):293–6.
Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–95.
Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713. quiz 786–8.
Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365:44–53.
• Mehari A, Gladwin MT, Tian X, et al. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254–6. Analysis of PHTN as an independent predictor of mortality using right heart catherization.
Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49:472–9.
Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175:1272–9.
Lewis JF, Maron BJ, Castro O, Moosa Y. Left ventricular diastolic filling abnormalities identified by doppler echocardiography in asymptomatic patients with sickle cell anemia. JACC. 1991;17(7):1473–8.
Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther. 1994;8:101–10.
Batra AS, Acherman RJ, Wong WY, et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol. 2002;70:306–12.
• Hankins JS, McCarville MB, Hillenbrand CM, et al. Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition. Pediatr Blood Cancer. 2010;55(3):495–500. Highlights need for alternative explanations of ventricular diastolic dysfunction.
Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257–61.
Hannoush H, Kato GJ, Machado RF, et al. A lower tissue Doppler E/Ea threshold predicts elevated pulmonary capillary wedge pressure in sickle cell patients (abstr). J Am Soc Echocardiogr. 2011;24:B18.
Covitz W, Espeland M, Gallagher D, et al. The heart in sickle cell anemia. The cooperative study of sickle cell disease (CSSCD). Chest. 1995;108:1214–9.
Poludasu S, Ramkissoon K, Salciccioli L, et al. Left ventricular systolic function in sickle cell anemia: a meta-analysis. J Card Fail. 2013;19(5):333–41.
Lamers L, Ensing G, Pignatelli R, et al. Evaluation of left ventricular systolic function in pediatric sickle cell anemia patients using the end-systolic wall stress-velocity of circumferential fiber shortening relationship. J Am Coll Cardiol. 2006;47:2283–8.
Mansi IA, Rosner F. Myocardial infarction in sickle cell disease. J Natl Med Assoc. 2002;94(6):448–52.
Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Myocardial injury or infarction associated with fat embolism in sickle cell disease: a report of three cases with survival. Am J Hematol. 2005;80:133–6.
• Chacko P, Kraut EH, Zweier J, et al. Myocardial infarction in sickle cell disease: use of translational imaging to diagnose an under-recognized problem. J Cardiovasc Transl Res. 2012. Illustates gaps in methods of diagnoses.
Barnett O, Saunders DE, McFarland DE, et al. Myocardial infarction in sickle cell anemia. Am Heart J. 1984;16:139–47.
Oguanobi NI, Ejim EC, Anisiuba BC, et al. Electrocardiographic findings in sickle cell cardiovascular autonomic neuropathy. Clin Auton Res. 2012;22(3):137–45.
•• Bode-Thomas F, Hyacinth HI, Ogunkunle O, Omotoso A. Myocardial ischaemia in sickle cell anaemia: evaluation using a new scoring system. Ann Tropical Paediatr. 2011;31:67–74. Highlights considerations that should be made in diagnosing myocardial ischemia in SCD during pain crises.
James TN. Homage to James B. Herrick: a contemporary look at myocardial infarction and at sickle-cell heart disease: the 32nd Annual Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2000;101:1874–99.
Pannu R, Zhang J, Andraws R, Armani A, et al. Acute myocardial infarction in sickle cell disease: a systematic review. Crit Pathw Cardiol. 2008;7:133–8.
• Bratis K, Kattamis A, Athanasiou K, et al. Abnormal myocardial perfusion-fibrosis pattern in sickle cell disease assessed by cardiac magnetic resonance imaging. Int J Cardiol. 2013;166(3):e75–6. Illustrates diffuse fibrosis suggesting alternative to previous beliefs about diagnosing fibrosis.
Pavlu J, Ahmed RE, O’Regan DP, et al. Myocardial infarction in sickle-cell disease. Lancet. 2007;369:246.
Maisel A, Friedman H, Flint L, et al. Continuous electrocardiographic monitoring in patients with sickle-cell anemia during pain crisis. Clin Cardiol. 1983;6(7):339–44.
Sangkatumvong S, Coates TD, Khoo MC. Abnormal autonomic cardiac response to transient hypoxia in sickle cell anemia. Physiol Meas. 2008;29(5):655–68.
Mueller BU, Martin KJ, Dreyer W, et al. Prolonged QT interval in pediatric sickle cell disease. Pediatr Blood Cancer. 2006;47(6):831–3.
Liem RI, Young LT, Thompson AA. Prolonged QTc interval in children and young adults with sickle cell disease at steady state. Pediatr Blood Cancer. 2009;52(7):842–6.
Harris KM, Haas TS, Eichner ER, Maron BJ. Sickle cell trait associated with sudden death in competitive athletes. Am J Cardiol. 2012;110(8):1185–8.
Loosemore M, Walsh SB, Morris E, Stewart G, Porter JB, Montgomery H. Sudden exertional death in sickle cell trait. Br J Sports Med. 2012;46:312–4.
Fontaine JM, Ofili EO, Adenaike MB, et al. Clinical assessment of the risk for sudden cardiac death in patients with sickle cell anemia. J Natl Med Assoc. 2000;100:360–8.
Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–63.
Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103–5.
Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–6.
Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging. 2007;26(3):564–8.
•• Hoppe C, Kuypers F, Larkin S, Hagar W, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011;153(5):655–63. Only clinical trial of statins in SCD.
Wang H, Luo W, Wang J, et al. Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease. Br J Haematol. 2013;162(1):120–9.
• Zorca S, Freeman L, Hildesheim M, et al. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. Br J Haematol. 2010;149(3):436–45. Offers link to triglycerides and PHTN.
Elsharawy MA, Moghazy KM, Shawarby MA. Atherosclerosis in sickle cell disease - a review. Int J Angiol. 2009;18(2):62–6.
Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38(8):1237–43.
Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis. 2004;15(5):235–42.
• Adam SS, Hoppe C. Potential role for statins in sickle cell disease. Pediatr Blood Cancer. 2013;60(4):550–7. Comprehensive review of potential statin use in SCD.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
Albert MA, Glynn RJ, Fonseca FA, et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. 2011;162(1):106–14.e2.
Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326(14):910–5.
• Farrell K, Dent L, Nguyen ML, et al. The relationship of oxygen transport and cardiac index for the prevention of sickle cell crises. J Natl Med Assoc. 2010;102(11):1000–7. Offers important alternative view to managing pain crises in SCD.
Lima CS, Ueti OM, Ueti AA, et al. Enalapril therapy and cardiac remodelling in sickle cell disease patients. Acta Cardiol. 2008;63(5):599–602.
Compliance with Ethics Guidelines
Conflict of Interest
Aryana S. Jacobs, Hakeem O. Ayinde, and Dexter L. Lee, declare that they have no conflict of interest
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jacobs, A.S., Ayinde, H.O. & Lee, D.L. Inflammatory Biomarkers and Cardiovascular Complications in Sickle Cell Disease: A Review. Curr Cardiovasc Risk Rep 7, 368–377 (2013). https://doi.org/10.1007/s12170-013-0325-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12170-013-0325-x